Communiqués Keros Therapeutics, Inc.

Actions

KROS

US4923271013

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 23/07/2026			Varia. 5j.	Varia. 1 janv.
10,14 ^USD	-0,69%		-4,43%	-50,20%

22/07	Keros Therapeutics, Inc. annonce la nomination d'Annita Tanini au poste de responsable comptable par intérim, à compter du 4 août 2026	CI
25/06	Keros Therapeutics, Inc. annonce la nomination d'Anne Prener en tant qu'administratrice, à compter du 1er juillet 2026	CI

Communiqués

25/06	Keros Therapeutics Appoints Anne Prener to its Board of Directors	AQ
01/06	Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference	AQ
14/05	Keros Therapeutics Reports Recent First Quarter 2026 Financial Results	AQ
09/03	Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS	AQ
09/03	Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference	AQ
04/03	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results	AQ
26/02	Keros Therapeutics Appoints Charles Newton to its Board of Directors	AQ
18/02	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences	AQ
20/11	Keros Therapeutics Announces Final Results of Tender Offer	AQ
19/11	Keros Therapeutics Announces Preliminary Results of Tender Offer	AQ
05/11	Keros Therapeutics Reports Third Quarter 2025 Financial Results	AQ
20/10/25	Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares	AQ
15/10/25	Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital	AQ
08/09/25	Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting	AQ
28/08/25	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences	AQ
21/08/25	ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment	PR
20/08/25	Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy	AQ
06/08/25	Keros to Exclusively Prioritize the Clinical Advancement of KER-065	AQ
06/08/25	Keros Therapeutics Reports Second Quarter 2025 Financial Results	AQ
17/07/25	Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept	AQ
09/06/25	ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal	PR
09/06/25	Keros Announces Return of $375 Million in Excess Capital to Stockholders	AQ
06/06/25	Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference	AQ
29/05/25	Keros Therapeutics : Results from the Cibotercept TROPOS PAH Phase 2 Trial (8f19c4)	PU
29/05/25	Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring	AQ